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Sir,
In a recent study, Marotta et al (2003) reported integrin-linked
kinase (ILK) overexpression and dysregulation of ILK signalling in
sporadic human colon cancer. It was concluded that the
dysregulation of ILK signalling is an important early event in the
development of the disease.
We studied ILK expression in 84 human colorectal tumours
(four adenomas and 80 carcinomas) by immunohistochemistry in
order to assess whether ILK is involved in the development and
progression of human colorectal carcinoma. Paraffin-embedded
tissue samples were retrieved from the files of the Departments of
Pathology, ‘Agios Andreas’ General Hospital, Patras, Greece and
University Hospital of Ioannina, Ioannina, Greece. Clinicopatho-
logic parameters were obtained from the pathology reports.
Carcinomas were graded as: well, moderately and poorly
differentiated on the basis of the degree of gland formation and
staged according to the Astler Coller staging system. Immunohis-
tochemical analysis was carried out using a standard streptavidin–
biotin–peroxidase technique. Primary polyclonal anti-ILK anti-
body was obtained from Upstate Biotechnology (dilution 1:500),
and immunodetection was performed with StrAvigen Multilink
Immunodetection system B-SA (Biogenex) using DAB as the
chromogen. Negative and positive controls were used in the study.
The immunostaining intensity was evaluated by light microscopy
and scored as negative ( ), weak (þ), moderate (þþ) and
strong (þþþ). Statistical analysis was performed with SPSS 10
for Windows. Relationships between ILK expression and clinico-
pathologic parameters were evaluated by one-way ANOVA and
Tukey test post-hoc analysis. P-valueso0.05 were considered to be
significant.
There was no ILK immunoreactivity in the normal colonic
epithelium (Figure 1A, B), while the majority of adenomas (75%)
and in situ carcinomas (83.3%) were ILK positive (Figure 1C, D).
All invasive carcinomas were positive (Figure 1E, F). The levels
of expression were significantly higher in invasive compared
with noninvasive lesions (Po0.001). The intensity of ILK
expression was also correlated with the depth of invasion
(Po0.001), presence of lymph node metastasis (Po0.01), tumour
grade (Po0.001) (Figure 2) and overall staging (Po0.001)
(Table 1). In all positive lesions, 490% of tumour cells were
stained (diffuse pattern) and ILK immunostaining was confined to
the cytoplasm.
Our results seem to indicate that, in addition to being involved
in the initiation of colon carcinogenesis, as suggested by
Marotta et al (2003), ILK may also be implicated in the
progression, invasiveness and metastatic potential of colorectal
cancer. Thus, ILK may prove to be a useful prognostic marker for
these tumours.
Figure 1 Integrin-linked kinase expression in human colorectal tumours.
(A) Normal colonic epithelium with no ILK immunoreactivity ( 200). (B)
Integrin-linked kinase-positive cancerous crypts compared with ILK-negative
normal crypts ( 200). (C, D) Weak (þ) immunostaining in an adenoma
and an in situ carcinoma, respectively ( 200). (E, F) Invasive carcinomas
demonstrating strong (þþþ) immunostaining ( 200).
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Table 1 Integrin-linked kinase expression in human colorectal tumours.
Correlation with clinicopathologic parameters
ILK expression
  + ++ +++
Nn % n % n % n % P-value
a
Adenomas total 4 1 (25) 3 (75) 0 (0) 0 (0)
Carcinomas total 80 2 (2.5) 23 (28.7) 40 (50) 15 (18.8)
Invasive 68 0 (0) 18 (26.5) 35 (51.5) 15 (22) o0.001
In situ 12 2 (16.6) 5 (41.7) 5 (41.7) 0 (0)
Depth of invasion o0.001
Tis 12 2 (16.6) 5 (41.7) 5 (41.7) 0 (0)
T1+T2 8 0 (0) 5 (62.5) 3 (37.5) 0 (0)
T3+T4 60 0 (0) 13 (21.7) 32 (53.3) 15 (25)
Lymph node metastasis 35 0 (0) 7 (20) 16 (45.7) 12 (34.3) o0.01
Grade o0.001
Well differentiated 16 2 (12.5) 8 (50) 6 (37.5) 0 (0)
Moderately differentiated 37 0 (0) 10 (27) 21 (56.8) 6 (10.2)
Poorly differentiated 27 0 (0) 5 (18.5) 13 (48.2) 9 (33.3)
Astler Coller stage o0.001
A 12 2 (16.6) 5 (41.7) 5 (41.7) 0 (0)
B1 8 0 (0) 5 (62.5) 3 (37.5) 0 (0)
B2 25 0 (0) 6 (24) 16 (64) 3 (12)
C1 0 0 (0) 0 (0) 0 (0) 0 (0)
C2 35 0 (0) 7 (20) 16 (45.7) 12 (34.3)
aOne-way ANOVA. P-valueo0.05 statistically significant.
Figure 2 Integrin-linked kinase expression increases with tumour grade.
(A) A well-differentiated colorectal carcinoma demonstrating weak (þ)
ILK expression ( 200). (B) Moderate levels of expression (þþ)i na
moderately differentiated tumour ( 200). (C) High levels of expression
(þþþ) in a poorly differentiated neoplasm ( 200).
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